Serum Progranulin Predicts High Activity of ANCA-Associated Vasculitis
|
By LabMedica International staff writers Posted on 18 Oct 2021 |

Image: Schematic diagram showing Anti-Neutrophil cytoplasmic antibody ANCA-induced ‘activation’ of neutrophils causing inflammation of the blood vessel wall (Photo courtesy of Addenbrooke’s Hospital)
Anti-Neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of chronic multisystem autoimmune diseases with substantial mortality and morbidity and frequent relapses. Progranulin is known to assume both pro-inflammatory roles and anti-inflammatory roles in the immune response.
The complexity of the disease condition and treatment-related adverse reactions as well as infections plays important roles in the poor outcomes. Unfortunately, the subjective symptoms and objective indicators are not fully parallel, and manifestations between disease activity and treatment-related adverse reactions are often similar.
Medical Scientists at the Yonsei University College of Medicine (Seoul, Republic of Korea) selected 58 AAV patients with consecutive hospital identity numbers and were first diagnosed with AAV at their hospital between January 2019 and December 2020. Data regarding age, sex, AAV subtypes, ANCAs, and organ involvement were collected from patients during the visit for blood sample collection. The laboratory data, white blood cell and platelet counts, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), hemoglobin, glucose, blood urea nitrogen, serum creatinine, total protein, serum albumin, and complements 3 and 4 were collected. Serum progranulin concentration was quantified by ELISA kits (R&D Systems, Minneapolis, MN, USA).
The investigators reported that the median age of patients was 63.0 years and 19 were men. The median BVAS was 11.0, and the median serum progranulin level was 49.0 ng/mL. Serum progranulin was significantly correlated with Birmingham Vasculitis activity score (BVAS), Five-Factor Score (FFS), erythrocyte sedimentation rate, C-reactive protein level, SF-36 PCS, hemoglobin, and serum albumin. Severe AAV was arbitrarily defined as the highest tertile of BVAS (BVAS ≥16). When the cut-offs of serum progranulin were set as 55.2 ng/mL and 43.01 ng/mL for severe AAV, AAV patients with serum progranulin ≥55.2 and 43.01 ng/mL had significantly higher risks of severe AAV than those without (relative risk (RR) 4.167 and 4.524, respectively).
The authors concluded that progranulin might play an anti-inflammatory role in AAV pathogenesis and serum progranulin could be used as a predictive marker for high activity of AAV. The study was published on October 9, 2021 in the Journal of Clinical Laboratory Analysis.
Related Links:
Yonsei University College of Medicine
R&D Systems
The complexity of the disease condition and treatment-related adverse reactions as well as infections plays important roles in the poor outcomes. Unfortunately, the subjective symptoms and objective indicators are not fully parallel, and manifestations between disease activity and treatment-related adverse reactions are often similar.
Medical Scientists at the Yonsei University College of Medicine (Seoul, Republic of Korea) selected 58 AAV patients with consecutive hospital identity numbers and were first diagnosed with AAV at their hospital between January 2019 and December 2020. Data regarding age, sex, AAV subtypes, ANCAs, and organ involvement were collected from patients during the visit for blood sample collection. The laboratory data, white blood cell and platelet counts, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), hemoglobin, glucose, blood urea nitrogen, serum creatinine, total protein, serum albumin, and complements 3 and 4 were collected. Serum progranulin concentration was quantified by ELISA kits (R&D Systems, Minneapolis, MN, USA).
The investigators reported that the median age of patients was 63.0 years and 19 were men. The median BVAS was 11.0, and the median serum progranulin level was 49.0 ng/mL. Serum progranulin was significantly correlated with Birmingham Vasculitis activity score (BVAS), Five-Factor Score (FFS), erythrocyte sedimentation rate, C-reactive protein level, SF-36 PCS, hemoglobin, and serum albumin. Severe AAV was arbitrarily defined as the highest tertile of BVAS (BVAS ≥16). When the cut-offs of serum progranulin were set as 55.2 ng/mL and 43.01 ng/mL for severe AAV, AAV patients with serum progranulin ≥55.2 and 43.01 ng/mL had significantly higher risks of severe AAV than those without (relative risk (RR) 4.167 and 4.524, respectively).
The authors concluded that progranulin might play an anti-inflammatory role in AAV pathogenesis and serum progranulin could be used as a predictive marker for high activity of AAV. The study was published on October 9, 2021 in the Journal of Clinical Laboratory Analysis.
Related Links:
Yonsei University College of Medicine
R&D Systems
Latest Hematology News
- New Guidelines Aim to Improve AL Amyloidosis Diagnosis
- Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
- Fast and Easy Test Could Revolutionize Blood Transfusions
- High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
- AI Algorithm Effectively Distinguishes Alpha Thalassemia Subtypes
- MRD Tests Could Predict Survival in Leukemia Patients
- Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
- Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
- ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
- Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage
- Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments
- Platelets Could Improve Early and Minimally Invasive Detection of Cancer
- Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment
- Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
- First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes

- New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







